Bose S - Search Results

1

Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.

Telli ML, Hellyer J, Audeh W, Jensen KC, Bose S, Timms KM, Gutin A, Abkevich V, Peterson RN, Neff C, Hughes E, Sangale Z, Jones J, Hartman AR, Chang PJ, Vinayak S, Wenstrup R, Ford JM. Telli ML, et al. Among authors: bose s. Breast Cancer Res Treat. 2018 Apr;168(3):625-630. doi: 10.1007/s10549-017-4624-7. Epub 2017 Dec 23. Breast Cancer Res Treat. 2018. PMID: 29275435

2

Stratifying triple-negative breast cancer prognosis using 18F-FDG-PET/CT imaging.

Yue Y, Cui X, Bose S, Audeh W, Zhang X, Fraass B. Yue Y, et al. Among authors: bose s. Breast Cancer Res Treat. 2015 Oct;153(3):607-16. doi: 10.1007/s10549-015-3558-1. Epub 2015 Sep 7. Breast Cancer Res Treat. 2015. PMID: 26346756 Free PMC article.

3

BRCA-mutated Invasive Breast Carcinomas: Immunohistochemical Analysis of Insulin-like Growth Factor II mRNA-binding Protein (IMP3), Cytokeratin 8/18, and Cytokeratin 14.

Mohanty SK, Lai JP, Gordon OK, Pradhan D, Bose S, Dadmanesh F. Mohanty SK, et al. Among authors: bose s. Breast J. 2015 Nov-Dec;21(6):596-603. doi: 10.1111/tbj.12494. Epub 2015 Sep 22. Breast J. 2015. PMID: 26390986

4

Triple-negative Breast Carcinoma: Morphologic and Molecular Subtypes.

Bose S. Bose S. Adv Anat Pathol. 2015 Sep;22(5):306-13. doi: 10.1097/PAP.0000000000000084. Adv Anat Pathol. 2015. PMID: 26262513 Review.

5

Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.

Yue Y, Astvatsaturyan K, Cui X, Zhang X, Fraass B, Bose S. Yue Y, et al. Among authors: bose s. PLoS One. 2016 Mar 1;11(3):e0149661. doi: 10.1371/journal.pone.0149661. eCollection 2016. PLoS One. 2016. PMID: 26930401 Free PMC article.

6

Androgen receptor positive triple negative breast cancer: Clinicopathologic, prognostic, and predictive features.

Astvatsaturyan K, Yue Y, Walts AE, Bose S. Astvatsaturyan K, et al. Among authors: bose s. PLoS One. 2018 Jun 8;13(6):e0197827. doi: 10.1371/journal.pone.0197827. eCollection 2018. PLoS One. 2018. PMID: 29883487 Free PMC article.

7

Comparison of Magee and Oncotype DX Recurrence Scores in estrogen receptor positive breast cancers.

Walts AE, Mirocha JM, Bose S. Walts AE, et al. Among authors: bose s. Breast J. 2018 Nov;24(6):951-956. doi: 10.1111/tbj.13108. Epub 2018 Sep 19. Breast J. 2018. PMID: 30230113

8

Unmasking of epigenetically silenced genes reveals DNA promoter methylation and reduced expression of PTCH in breast cancer.

Wolf I, Bose S, Desmond JC, Lin BT, Williamson EA, Karlan BY, Koeffler HP. Wolf I, et al. Among authors: bose s. Breast Cancer Res Treat. 2007 Oct;105(2):139-55. doi: 10.1007/s10549-006-9440-4. Epub 2007 Feb 13. Breast Cancer Res Treat. 2007. PMID: 17295047

9

Prediction of additional axillary metastasis of breast cancer following sentinel lymph node surgery.

Changsri C, Prakash S, Sandweiss L, Bose S. Changsri C, et al. Among authors: bose s. Breast J. 2004 Sep-Oct;10(5):392-7. doi: 10.1111/j.1075-122X.2004.21446.x. Breast J. 2004. PMID: 15327491

10

Basal Protein Expression Is Associated With Worse Outcome and Trastuzamab Resistance in HER2+ Invasive Breast Cancer.

Chung A, Choi M, Han BC, Bose S, Zhang X, Medina-Kauwe L, Sims J, Murali R, Taguiam M, Varda M, Schiff R, Giuliano A, Cui X. Chung A, et al. Among authors: bose s. Clin Breast Cancer. 2015 Dec;15(6):448-457.e2. doi: 10.1016/j.clbc.2015.06.001. Epub 2015 Jun 19. Clin Breast Cancer. 2015. PMID: 26248960 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,513 results

Search Page

Filters